Subscribe to feed

Our Perspectives

Prostate Cancer

About the Genomic Health Oncotype DX Prostate Cancer Test

Prostate cancer screenings occur in 23 million men each year, with 240,000 being diagnosed with the affliction. In less severe cases, patients are quick to receive immediate treatment despite the fact that only 3% are likely to have a prostate cancer recurrence. Genomic Health provides a test for prostate cancer patients, called the Oncotype DX prostate cancer test (assay), which helps determine how aggressive the prostate cancer is and can help doctors and patients individualize their course of treatment. Allowing a man to make an informed decision about his prostate cancer treatment options. Taking care of himself, his quality of life, and…giving him peace of mind. Learn more:

Learn more about the Oncotype DX prostate cancer test